Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
- 31 January 2000
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 36 (2), 200-206
- https://doi.org/10.1016/s0959-8049(99)00249-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.Journal of Clinical Oncology, 1998
- Adjuvant radiotherapy to sites of previous bulky disease in patients stage iv diffuse large cell lymphomaInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Second cancer risk following Hodgkin's disease: a 20-year follow-up study.Journal of Clinical Oncology, 1994
- Late cardiac effects after mantle radiotherapy in patients with Hodgkin's diseaseAnnals Of Oncology, 1990
- Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.Journal of Clinical Oncology, 1988
- The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease.Journal of Clinical Oncology, 1988
- Residual fibrous masses in treated Hodgkin's diseaseCancer, 1987
- Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for hodgkin's diseaseInternational Journal of Radiation Oncology*Biology*Physics, 1985
- The significance of the residual mediastinal mass in treated Hodgkin's disease.Journal of Clinical Oncology, 1985
- Residual Abdominal Masses Following Treatment of Hodgkin's DiseaseAustralasian Radiology, 1980